宫颈癌,女性第三大常见癌症,几乎所有病例都是由高危型人乳头瘤病毒持续感染引起的。尽管人乳头瘤病毒感染80%-90%是短暂的,并在24个月内自发消失,仍然存在的人乳头瘤病毒感染有发生宫颈病变的风险。已经测试了不同的治疗方法来促进低度病变的消退或防止进展。它们包括5-氟尿嘧啶的应用,姜黄素,咪喹莫特,干扰素,维生素D,和其他人。此外,我们评估了益生菌和羧甲基β葡聚糖阴道治疗的效果.介绍了文献综述和最后一项研究数据的介绍。通过使用含有高度分散的SiO2和柠檬酸和钠的抗氧化组合的新型阴道凝胶治疗,似乎可以促进高危人乳头瘤病毒的清除。这种凝胶显示,6个月后,细胞学巴氏检查结果的改善(ASC-US,LSIL,ASC-H,或HSIL)在80.9%的参与者中。同样,给予凝胶3个月后,53%的病例清除了hr-人乳头瘤病毒。未治疗对照组的百分比从基线时的78.3%略微增加至3个月后的83%。在6个月后,p16/Ki67检测呈阳性的患者百分比从基线时的75%下降到治疗组的5.3%。而非治疗组的百分比仅略有下降(基线:91.5%;6个月:75.2%)。检查的阴道凝胶可能支持明显的细胞学发现的愈合(ASC-US,LSIL,ASC-H,或HSIL)和清除hr-人乳头瘤病毒阳性结果。
Cervical cancer, the third most common cancer in women, is caused in nearly all cases by a persistent infection with high-risk types of the human papillomavirus. Although human papillomavirus infections are 80%-90% transient and disappear spontaneously within 24 months, human papillomavirus infections that remain are at risk of developing cervical lesions. Different therapeutical approaches have been tested to promote the regression of low-grade lesions or prevent progression. They include the application of 5-fluorouracil, curcumin, imiquimod, interferons, Vitamin D, and others. Also, the effect of probiotics and vaginal therapy with carboxy-methyl-beta glucan was assessed.
Review of the literature and presentation of the last study data are presented. Clearance of high-risk human papillomavirus seemed to be promoted by treatment with a new vaginal gel containing a highly disperse SiO2 and an anti-oxidative combination of citric acid and sodium. This gel showed, after 6 months, an improvement of cytological Pap findings (ASC-US, LSIL, ASC-H, or HSIL) in 80.9% of the participants. Similarly, there was a clearing of hr-human papillomavirus in 53% of cases after 3 months of gel administration. The percentage increased slightly in the non-treated control group from 78.3% at baseline to 83% after 3 months. The percentage of patients who were tested positive for p16/Ki67 reduced from 75% at baseline to 5.3% in the treatment group after 6 months, while the percentage decreased only slightly in the non-treated group (baseline: 91.5%; 6 months: 75.2%). The examined vaginal gel may support the healing of conspicuous cytological findings (ASC-US, LSIL, ASC-H, or HSIL) and clearance of hr-human papillomavirus positive results.